Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Podcast for Multiple Myeloma: Noopur Raje, MD, Mass General

  • Broadcast in Health
HealthTree Podcast for MM

HealthTree Podcast for MM

×  

Follow This Show

If you liked this show, you should follow HealthTree Podcast for MM.
h:539173
s:11927776
archived

CAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of other therapies. Ide-cel (Abecma) is a product developed by Bristol Myers Squibb and blubird bio. 

Thanks to our episode sponsor, Oncopeptides

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled